Aliri Bioanalysis Announces Executive Leadership Appointments
May 1, 2025 – Aliri Bioanalysis, a leading provider of advanced bioanalytical and spatial multi-omics solutions for drug developers, today announced the appointment of Steve Lundy as Chief Executive Officer, and Kevin Jones as Chief Operating Officer. This exciting transition in leadership marks a pivotal moment in Aliri’s evolution, as the company accelerates its strategic growth initiatives and further strengthens its commitment to customer excellence and service delivery.
Aliri Launches CyTOF Inflammatory Response Assay as Powerful Single-Method Alternative to Flow Cytometry and Ligand Binding Assays
April 7, 2025 – Aliri Bioanalysis, a leading provider of advanced bioanalytical and spatial multi-omics solutions for drug developers, is pleased to announce the launch of Cytometry by Time-Of-Flight (CyTOF), an advanced bioanalysis technique that combines aspects of flow cytometry with mass spectrometry to analyze single cells with high precision.
Aliri Launches qPCR to Complement Existing Lineup of Multi-omics Platforms
January 22, 2025 – Aliri Bioanalysis, a leading provider of advanced bioanalytical and spatial biology solutions for drug developers, is pleased to announce the addition of quantitative polymerase chain reaction analysis (qPCR) to our extensive list of analytical services. The implementation of this technology complements our existing lineup of multi-omics platforms, making Aliri a one-stop-shop for the advanced GCP analysis of fluids and tissues.
Aliri Celebrates 30 Years of Bioanalytical Excellence and Scientific Innovation during AAPS
October 21, 2024 – Aliri Bioanalysis is pleased to announce its upcoming participation at the American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 Annual Meeting this week in Salt Lake City, Utah. This year’s event holds special significance as Aliri celebrates the30th anniversary of its Salt Lake City, Utah laboratory (formerly Tandem Labs).
Experts to Showcase Innovative Research at ASMS
May 29, 2024 – Aliri, a leading provider of advanced bioanalytical and spatial biomarker solutions for drug developers, will be participating at the upcoming American Society for Mass Spectrometry (ASMS) Conference, taking place from June 2-6, 2024, in Anaheim, CA. Aliri’s experts will present four scientific posters highlighting the company’s advancements in pharmacokinetics, biomarker assay development, and analytical techniques.
Scientific Leaders to Present at WRIB in San Antonio
May 2, 2024 – Aliri, a leading provider of advanced bioanalytical lab and spatial biomarker solutions for drug developers, today announced that three of its scientific experts will present at the upcoming Workshops on Recent Issues in Bioanalysis (WRIB) conference, to be held at the Marriott Rivercenter in San Antonio on May 6-10, 2024. The company also encourages attending sponsors to meet with its team at exhibit booth #21 during the conference.
Former Pyxant Labs and ImaBiotech Announce New Unified Brand as Aliri
May 23, 2023 - The bioanalytical CRO companies formerly known as Pyxant Labs Inc. and ImaBiotech Group, which joined forces in 2021, are pleased to announce their new identity as Aliri. The integrated company's goal is to provide pharma and biotech companies a seamless experience across a unique range of decisive and innovative services, including mass spectrometry and imaging techniques for bioanalysis, spatial bioanalysis, and spatial biology. Aliri's team of seasoned scientists, project managers, and technical and regulatory experts remains dedicated to partnering with visionary drug developers and adding value to their workflow.